HDAC2 and neoplasm: Previous studies have shown that HDAC inhibitors can suppress the activity of class I HDACs, including HDAC2, inducing cell cycle arrest, apoptosis, and DNA damage in BCa cells, thereby impairing tumor progression and overcoming resistance to PARP inhibitors and cisplatin [36, 37].